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1 Introduction 
Brain metastases are frequent complications for cancer patients (10%–30%) and 
result in high mortality rate. The overall life expectancy is limited to a few months (4–5 
months) even after intensive multimodal therapy (Fokas, Steinbach & Rodel 2013). 
Estimations of occurrence show that in the United States brain metastases are 10 
times more common than primary malignant brain tumors (Davis et al. 2012, Platta et al. 
2010). Metastatic cells of different origin display considerable differences in the tendency 
to access the central nervous system (CNS), with lung cancer (40%–50%), followed by 
breast cancer (15%–25%) and malignant melanoma (5%–20%) resulting most frequently 
in brain metastasis (Wen, Black & Loeffler 2011, Barnholtz-Sloan et al. 2004). Among 
these tumors, melanoma is most prone to form brain metastases: diagnosed in 40%–50% 
of the cases, which after autopsy, increase with an additional 30%–40%. Emergence of 
metastases involves multistep processes: from tumor cells invading the local tissue and 
entering the blood or lymphatic vessels, to extravasation and colonization of the target 
organs. Since the central nervous system lacks a lymphatic drainage, metastatic tumor 
cells can reach the brain only via the blood vessels. However, between the blood and the 
CNS there are barrier interfaces, including the blood-cerebrospinal fluid (CSF) barrier, 
the arachnoid epithelium between blood and subarachnoid CSF and the blood-brain 
barrier (BBB). To colonize the brain parenchyma tumor cells have to pass mainly the 
blood-brain barrier. 
1.1 The blood-brain barrier 
The blood-brain barrier is an active interface between the circulation and the 
central nervous system, and has an important role in maintaining the homeostasis of the 
CNS. This is achieved by the control of the ion balance, nutrient supply as well as 
through elimination of metabolic compounds. Hence, the BBB has dual task, operates 
both as a barrier and as a carrier too.  
As a barrier, it restricts the transport of potentially toxic or harmful substances 
from the blood to the brain, which is secured through a fourfold defense line:  
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i. The interendothelial tight junctions form the paracellular barrier and are 
responsible for regulation of ion and solute movement between adjoining 
cells.  
ii. Brain endothelial cells show low level of endocytosis and transcytosis thus 
conferring a transcellular barrier.  
iii. The enzymatic barrier results from a complex set of enzymes including 
acetyl-cholinesterase, alkaline phosphatase, gamma-glutamyl 
transpeptidase, monoamine oxidases, and other drug metabolizing 
enzymes capable to degrade different chemical compounds. 
iv. Nevertheless, the presence of efflux transporters (ATP-binding cassette 
(ABC) transporters) at the cerebral endothelium also has a critical role in 
BBB barrier function. The foremost ABC transporters are P-glycoprotein 
(P-gp, ABCB1), the multidrug resistance-associated proteins (MRPs: 
ABCC1 and ABCC4) and breast cancer resistance protein (BCRP, 
ABCG2).  
Beyond the barrier function, the BBB ensures the transport of nutrients to the 
brain and removal of metabolites. Blood oxygen and carbon dioxide, as well as small 
lipid soluble molecules diffuse passively across the endothelium. Cerebral endothelial 
cells (CECs) express a vast number of specific solute carriers (SLC) which transport 
essential nutrients like glucose and amino acids (Abbott et al. 2010). Some substances are 
transported through receptor mediated transcytosis (peptides and proteins) or by 
adsorptive transcytosis (positively charged molecules). 
The BBB functions as listed above are mainly provided by the endothelial cells 
(ECs) of brain capillaries. Formation and maintenance of the special barrier 
characteristics of cerebral endothelial cells are supported by pericytes and astrocytes 
(Figure 1). Additionally, the BBB together with neurons and microglial cells is part of the 
neurovascular unit (Abbott, Ronnback & Hansson 2006). 
Endothelial cells are ensheathed by a basal membrane, which consists mainly of 
collagen IV, fibronectin, laminin and proteoglycans. The extracellular matrix (ECM) 
participates in endothelial barrier responses by way of binding to endothelial cell surface 
integrins at focal adhesions. Disruption of the basal membrane might lead to alterations 
affecting the junctional proteins and the integrity of the barrier. In several pathological 
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conditions, impaired BBB properties have been associated to disruption of the 
extracellular matrix (Hawkins, Davis 2005). Furthermore, the basal membrane is involved 
in survival of tumor cells during brain colonization (Carbonell et al. 2009). 
 
 
Figure 1: Schematic diagram of the blood-brain barrier. The core anatomical structure of the BBB is 
formed by cerebral endothelial cells, which share common basal membrane with pericytes, and are 
covered by astrocytic endfeet. Endothelial cells are interconnected by a continuous line of tight 
junctions. The inset illustrates the molecular structure of the junctional complex. TJ = tight junction; 
AJ = adherens junction. 
Pericytes are located in the duplication of the basal membrane and play an 
important role in the regulation of endothelial proliferation, angiogenesis and 
inflammatory processes (Dore-Duffy 2008). Nevertheless, pericytes are required to 
support BBB integrity (Armulik et al. 2010). 
Astrocytic endfeet encircle the cerebral vessels, covering a significant part of the 
endothelial surface (Kacem et al. 1998). Astrocytes or astrocyte-conditioned media 
improve endothelial barrier functions. Astrocytes release important regulatory factors 
including TGF-beta, glial cell derived neurotrophic factor (GDNF) (Igarashi et al. 1999), 
interleukin-6 and basic fibroblast growth factor (Sobue et al. 1999). 
Neurons might also regulate important aspects of the BBB function and can 
induce the expression of BBB-related enzymes in cultured endothelial cells (Tontsch, 
4 
 
 
 
Bauer 1991); nevertheless, neuronal mediators affect cerebral blood flow and vessel 
dynamics. 
1.2 Intercellular Junctions 
Interendothelial junctions including tight junctions (TJs) and adherens junctions 
(AJs) (Figure 1, inset) seal the paracellular space between endothelial cells. Tight 
junctions can be visualized as belt-like structures at the apical region of the cells, forming 
a physical barrier that regulates paracellular movement of ions and solutes ("gate 
function"). Restriction of ion movement results in high transendothelial electrical 
resistance (TEER). Through separation of the apical and the basolateral membrane 
domains TJs contribute to the polarization of the cell ("fence function") (Gonzalez-
Mariscal et al. 2003). 
Tight junctions are formed by transmembrane proteins that seal the paracellular 
gap and peripheral proteins, which are located at the cytoplasmic surface of junctions and 
interact with the transmembrane components. Three families of integral membrane 
proteins represent the key components of TJs. First, the tetraspan proteins are represented 
by the Marvel (occludin (Furuse et al. 1993), tricellulin/MarvelD2, MarvelD3) and 
claudin families. Brain endothelial cells express only a few from the claudin family, 
mainly claudin-5 and to a smaller extent claudin -3, -10,-12, yet claudin-10 and -22 may 
also contribute to TJ formation at the BBB (Ohtsuki et al. 2008). The maintenance of low 
paracellular permeability is mainly controlled by claudin-5. Second, members of single 
span proteins of the immunoglobulin superfamily localize to ECs junctions, like 
endothelial specific adhesion molecule and junctional adhesion molecules (JAM-A, -B, 
-C) (Martin-Padura et al. 1998). Third, non-immunglobulin type single span proteins are 
represented by crumbs homolog 3 (CRB3) and Bves/Pop1 (Blood vessel epicardial 
substance), which are relevant mainly for epithelial cells (Bauer et al. 2011). 
Cytoplasmic scaffold proteins contain PDZ (Psd95/discs large/ZO-1) domains, 
which link transmembrane proteins to the actin cytoskeleton. These include zonula 
occludens (ZO)-1 (Stevenson et al. 1986) and ZO-2 (Gumbiner, Lowenkopf & Apatira 
1991). Besides PDZ domain proteins, the junctional plaque include cingulin (Citi et al. 
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1989) and JACOP (junction-associated coiled-coil protein)/paracingulin (Ohnishi et al. 
2004) . 
Scaffolding proteins (e.g. ZO proteins) recruit several signaling proteins to tight 
junctions. Protein kinases (A, B, C), mitogen activated protein kinases (MAPK) have 
been involved in the regulation of BBB properties. The small GTPase Rho and Rac 
proteins also regulate TJ assembly and disassembly of ECs. Activation of RhoA and its 
effector ROCK leads to permeability increase, whereas Rac activation is barrier 
protective (Terry et al. 2010, Gonzalez-Mariscal, Tapia & Chamorro 2008). 
Development and maintenance of tight junctions is supported by adherens 
junctions, which are located basolaterally to TJs and also form a continuous line along 
cell-cell boundaries. Adherens junctions (AJs) are ubiquitous and essential in the 
development of the vasculature, in initiation and maintenance of cell-cell junctions. 
Transmembrane proteins of adherens junctions are members of the cadherin family. 
Endothelial cells express mainly vascular endothelial (VE-) cadherin, an important 
determinant of vascular integrity, connected through the catenins (alpha, beta, and p120) 
to the cytoskeleton. The main role of catenins is to anchor the cadherin complex to the 
actin cytoskeleton, yet they also participate in cell and developmental signaling pathways 
(Stamatovic, Keep & Andjelkovic 2008). Additionally, the nectin-afadin system plays 
important role both in organization and in formation of AJs and TJs. Nectin is linked to 
afadin (AF6), and through afadin to actin, but might interact with TJ proteins (ZO-1, 
JAMs) too (Takahashi et al. 1999, Fukuhara et al. 2002). 
Integrity of the BBB has been reported to be compromised in several neurological 
disorders including cerebral ischemia, inflammation and brain tumors. Moreover, the 
BBB is actively involved in the transmigration of leukocytes and tumor cells during 
inflammation and metastasis formation. 
1.3 Interactions of melanoma cells with the blood-brain barrier 
1.3.1 Development of melanoma 
Melanoma is a malignant tumor that arises from melanocytes, the pigmented cells 
of the skin. Development of melanoma has several sequential steps starting from 
structurally normal melanocytes. Early melanoma shows a radial growth in the epidermis. 
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With the progression of melanoma, tumor cells extend into the dermis (vertical growth 
phase). At this stage, melanoma cells are able to enter blood or lymphatic vessels and 
develop metastases in distant organs (Meier et al. 1998). Conversion of melanocytes to 
melanoma involves several genetic and molecular changes. Genetic susceptibility (loss of 
CDKN2A locus, MC1R) and intermittent sun exposure are well known contributors to 
melanoma risk. On the other hand, somatic mutations that overactivate the Ras/MAPK 
pathway (NRAS and BRAF) or Ras/PI3K signaling (PTEN deleted or AKT activated) 
facilitate tumor cell growth, survival and invasion (Whiteman, Pavan & Bastian 2011, 
Hocker, Singh & Tsao 2008).  
Despite of being relatively rare compared with other skin cancers melanoma 
accounts for a large majority of skin cancer associated deaths. This is partially due to the 
high incidence of brain metastasis. Melanoma brain metastases may have 
intraparenchymal (49%), leptomeningeal (22%) and dural (32%) manifestations (Fidler et 
al. 1999). Migration of tumor cells through the BBB is a prerequisite of parenchymal 
brain metastasis formation. 
Interestingly, metastatic tumor cells are able to respond to different organ-specific 
stimuli, i.e. growth factors present in or produced by the target organ. A possible reason 
for the high incidence of melanoma brain metastases might be a homing behavior. Based 
on the "seed and soil" hypothesis metastatic tumor cells (seed) show a distinct preference 
for a given organ that is more susceptible (soil) and sustains tumor growth (Fidler 2011). 
Melanocytes originate from pluripotent neural crest cells, sharing an embryologic origin 
with neurons. Neurotrophins (present both in the skin and in the CNS) as well as 
neurotrophin-regulated heparanase have been ascribed to play a significant role in 
melanoma brain invasion (Denkins et al. 2004).  
1.3.2 Molecular mechanisms of extravasation of tumor cells 
In order to colonize the target organs tumor cells need to exit the vasculature 
(extravasation). Extravasation involves the arrest of tumor cells in the vasculature, 
passage through or between endothelial cells, termed transendothelial migration and the 
penetration through the subendothelial basal membrane. Studies of leukocyte 
extravasation revealed the main molecular aspects of leukocyte transendothelial migration 
that may be applied to understand cancer cell extravasation. The steps of transmigration 
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in the case of immune cells are rolling, adhesion and diapedesis/transmigration. The 
sequential steps – attachment (weak and stable adhesion), transmigration – of the 
extravasation process may show similarities between leukocytes and tumor cells. 
However, due to different physiological, molecular and mechanical characteristics of 
immune and metastatic cells, there may be significant differences. Conversely, to 
extravasating leukocytes, migrating tumor cells induce an irreversible impairment of the 
endothelium (Strell, Entschladen 2008, Wolburg, Wolburg-Buchholz & Engelhardt 
2005). 
The process of transendothelial migration of tumor cells is largely 
uncharacterized, and much of our knowledge comes from studies on endothelial cells of 
non-cerebral origin, which do not present the special BBB phenotype. Different cell 
surface and adhesion molecules, proteolytic enzymes and signaling pathways have been 
shown to facilitate invasive and migratory capacities of melanoma cells and their transfer 
through endothelial barriers.  
However, very few experimental data are available about the interaction of 
melanoma cells with brain endothelial cells. Key steps in formation of melanoma brain 
metastasis were determined by in vivo real-time imaging and proved to be the following: 
arrest at vascular branch points, extravasation, persistent close contacts to microvessels 
and perivascular growth by vessel cooption (Kienast et al. 2010). 
1.3.2.1 Surface molecules involved in melanoma extravasation 
The first step in melanoma extravasation is the attachment to the ECs. Several 
adhesion and junctional molecules are involved in this process. Expression of cognate 
ligands and receptors is required for tumor cell adhesion to endothelial cells. 
In initial adherence of tumor cells selectin-dependent mechanisms may have 
important role. Melanoma cells express sialyl Lewis x, which is a ligand for endothelial 
selectin (E-selectin) and might facilitate the attachment to ECs. It has been reported that 
melanoma brain metastasis formation was ablated by heparin, a potent inhibitor of 
selectin dependent interactions (Maraveyas et al. 2010). 
Neuronal cadherin (N-cadherin) is expressed by ECs as well as by melanoma cells 
and promotes the adhesion and transendothelial migration subsequently (Qi et al. 2006). 
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Integrins are well known to be involved in different cancer metastasis formation. 
In case of melanoma, the αvβ3 and α4β1 integrins were shown to facilitate the 
transendothelial migration (Voura et al. 2001) .  
Several members of the immunoglobulin superfamily of cell adhesion molecules 
are also key participants of tumor cells’ extravasation. For example intercellular adhesion 
molecule-1 (ICAM-1) (Ghislin et al. 2012), vascular cell adhesion molecule (VCAM-1) 
(Klemke et al. 2007) and JAMs (Ghislin et al. 2011) may contribute to the interaction of 
melanoma cells with the endothelium. MCAM/MUC18 (CD146) expression is elevated in 
melanoma cells compared to melanocytes, and mediates adhesion between melanoma and 
endothelial cells. 
In addition, expression of melanotransferrin on melanoma cells was found to 
correlate with increased transmigration of melanoma cells through the BBB (Rolland et 
al. 2009).  
1.3.2.2 Proteolytic enzymes implicated in the migration of melanoma cells 
Attachment of melanoma cells to endothelial cells is followed by the infiltration 
through the endothelium, which is facilitated by the produced and released proteases. 
Tumor-cell secreted proteolytic enzymes are implicated in different steps of cancer 
invasion and metastasis formation. Several enzymes promote the invasion of host tissue 
including matrix metalloproteases (MMPs), serine proteases and heparanase. Spreading 
and metastatic potential often correlates with the secreted and released MMPs and serine 
proteases, which are responsible for extracellular matrix (ECM) degradation.  
It has been shown that MMP-2 is responsible for brain metastasis formation of 
breast cancer (Mendes, Kim & Stoica 2005) and melanoma cells (Xie et al. 2006). MMPs 
might have a putative role in transendothelial migration of tumor cells through the BBB 
since proteins of the junctional complex are possible targets of these enzymes. MMP-2 
and MMP-9 mediate infiltration of leukemic cells through the BBB by disrupting TJ 
proteins (claudin-5, occludin and ZO-1 as well) (Feng et al. 2011). 
Melanoma cells express several serine proteases (plasmin, u-PA, seprase) which 
play a pivotal role in migration. Plasmin mediates melanoma crossing through the BBB 
and promotes development of brain metastasis (Perides et al. 2006). Seprase, also known 
as FAP (fibroblast activation protein), was identified as being expressed by malignant 
melanoma cells, mostly localized at the invadopodia of migrating cells (Monsky et al. 
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1994). Nevertheless, it was established that the u-PAR and seprase colocalize at the 
invadopodia of malignant melanoma cells (Artym et al. 2002). Interestingly, seprase plays 
an important role in early dissemination of melanoma from the skin (Waster et al. 2011). 
However, little is known about its role in melanoma cell transmigration through the brain 
endothelium. 
1.3.2.3 Signaling pathways involved in melanoma extravasation 
Several signaling pathways have been shown to play important role in the 
transendothelial migration of melanoma cells. Src kinase participates in melanoma 
transendothelial migration (Qi et al. 2005) as well as enhances Rho/ROCK independent 
movement of melanoma cells (Ahn, Sanz-Moreno & Marshall 2012). Melanoma cells 
capable of brain metastasis formation show an enhanced activity of the Yes tyrosine 
kinase as well (Marchetti et al. 1998) . 
The PI3K-AKT pathway regulates cell survival and proliferation; nevertheless, it 
is overactivated in metastatic melanoma cells. PI3K inhibition could reduce the 
transendothelial migration of melanoma cells through human umbilical vein endothelial 
cells (Peng et al. 2005).  
Activation of p38 MAPK and ERK1/2 promotes melanoma cell invasion (Colone 
et al. 2008). In addition, ERK1/2 was shown to be activated in brain endothelial cells 
being exposed to melanoma cell-conditioned media (Anfuso et al. 2009). 
In the metastatic dissemination tumor cell spreading is mediated through constant 
cytoskeletal remodeling. Rho-kinases (ROCK1 and ROCK2) are the main effectors of the 
small GTPase RhoA and RhoC, having several substrates (including the LIM-kinases and 
myosin light chain) involved in the regulation of the cytoskeleton. 
1.3.2.4 Types of cancer cell movement 
It has been shown that tumor cells are able to adopt two interconvertible types of 
movement, characterized by mesenchymal and amoeboid (rounded) phenotype (Figure 2). 
The mesenchymal type exhibits elongated cell morphology, large cellular protrusions and 
requires high Rac1 activity, reduced Rho/ROCK signaling and exracellular proteolysis. 
Conversely, amoeboid movement is dependent on elevated Rho/ROCK signaling that 
ensures for actomyosin contractility (Sahai, Marshall 2003). The possibility to switch 
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between these phenotypes allows tumor cells to successfully invade the different types of 
extracellular matrices (ECMs) (Sanz-Moreno et al. 2008). 
 
Figure 2: Schematic representation of the two types of movement acquired by cancer cells. Tumor 
cells are able to switch between a Rac dependent mesenchymal phenotype and a Rho/ROCK 
dependent amoeboid one to enhance their migration. 
It is not surprising therefore, that studies regarding the effects of ROCK inhibition 
on tumor cell motility, invasion and metastasis formation are contradictory and appear to 
depend on the tumor cell type. Inhibition of ROCKs has been shown to decrease the 
invasion and migration of lung (Yang et al. 2012, Xu et al. 2012, Yang et al. 2010), breast 
(Wyckoff et al. 2006) and hepatocellular carcinoma cells (Itoh et al. 1999). In contrast, in 
case of osteosarcoma (Yui et al. 2010), pancreatic carcinoma (Fujita et al. 2011), colon 
carcinoma (Vishnubhotla et al. 2012) and scirrhous gastric carcinoma (Matsuoka et al. 
2011) ROCK inhibitors promoted invasive and migratory properties of the cells. 
Regarding melanoma, inhibition of the Rho/ROCK signaling pathway was shown to alter 
the expression of tumor progression genes (Spencer et al. 2011), reduce proliferation 
(Routhier et al. 2010), tumor cell invasion and formation of lung metastases (Kidera et al. 
2010). 
Additionally, movement of tumor cells might also depend on the physico-
chemical and biological properties of the extracellular matrix or endothelial barrier they 
need to cross. Moreover, the Rho/ROCK pathway in both tumor and endothelial cells is 
likely to play a role in the transendothelial migration. Therefore, ROCK inhibitors might 
influence (additively or oppositely) this process from the side of both cell types. 
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2 Aims 
Despite therapeutic efforts, brain metastasis has remained one of the most feared 
complications among cancer patients. The incidence of CNS metastases is very common 
in patients with melanoma. In order to reach the brain tumor cells must breach the 
blood-brain barrier, which represents a formidable challenge for metastatic cancer cells. 
Currently there is still a lack of information on the molecular mechanisms of the 
formation of brain metastases. Most of our knowledge is based on tumor cell interaction 
with endothelium of non-cerebral origin. Therefore, in our studies we sought to describe 
molecular mechanisms involved in the interaction of melanoma cells with the brain 
endothelium. Our investigations addressed the following specific questions: 
1. Do melanoma cells affect the integrity of the BBB during transmigration? 
2. What is the route of transmigration of melanoma cells through the BBB? 
3. Which are the main proteases facilitating melanoma transendothelial 
migration? 
4. What is the role of Rho/ROCK signaling in melanoma brain metastasis 
formation? 
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3 Materials and Methods 
3.1 Cell culture and treatments 
Interaction of melanoma cells with the brain endothelium was studied using the 
following cell lines: the human microvascular cerebral endothelial cell line hCMEC/D3, 
the A2058 human melanoma cell line and the murine B16/F10 melanoma cell line. The 
hCMEC/D3 (Weksler et al. 2005) human cerebral endothelial cells (shortly D3) were 
grown on rat tail collagen-coated dishes in EBM-2 medium (Lonza) supplemented with 
EGM-2 Bullet Kit (Lonza) and 5% FBS (Sigma). A2058 human melanoma cells 
(obtained from the European Collection of Cell Cultures) were maintained in MEM 
(Sigma) supplemented with 5% FBS (Lonza) and Glutamax (Invitrogen). The B16/F10 
melanoma cell line was used to confirm the data obtained with human cells and in the in 
vivo experiments. B16/F10 murine melanoma cells were kept in RPMI medium (Sigma) 
supplemented with 5% FBS (Lonza) and Glutamax.  
For transmigration experiments primary rat brain endothelial cells (RBECs) were 
used because of their superior barrier characteristics. Primary rat brain endothelial cells 
(RBECs) were isolated from 2-week old rats. Briefly, after removal of meninges cerebral 
cortices were cut into small pieces and digested with 1 mg/ml collagenase type 2 (Sigma). 
After separation of myelin by centrifugation in 20% bovine serum albumin (BSA), a 
second digestion was performed with 1 mg/ml collagenase/dispase (Roche). Microvessel 
fragments were collected after 10 min 1000•g centrifugation on Percoll (Sigma) gradient, 
and plated onto fibronectin/collagen-coated dishes. Endothelial cells growing out of the 
microvessels were cultured in DMEM/F12 (Invitrogen), 10% plasma-derived serum (First 
Link) and growth factors. In the first two days, 4 µg/ml puromycin was added to remove 
contaminating cells. 
The serine protease inhibitor Pefabloc was used in a concentration of 200 µM in 
transmigration experiments. Y27632 (Tocris) and fasudil (Santa Cruz) (ROCK-I and 
ROCK-II inhibitors) were used in a concentration of 10 µM. Selective inhibition of Rho 
in either RBEC or melanoma cells was performed using CT04 (cell permeable C3 
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transferase exoenzyme from Clostridium botulinum inactivating the GTPases RhoA, 
RhoB, and RhoC, Cytoskeleton Inc.) in a concentration of 1 µg/ml for 150 min.  
3.2 Adhesion experiments 
Brain endothelial cells (RBEC or D3) were grown until confluence in 24-well 
plates. Melanoma cells (A2058 or B16/F10) were fluorescently labeled using Oregon 
Green® 488 carboxylic acid diacetate succinimidyl ester (shortly: OG, Life technologies) 
using the protocol supplied by the manufacturer. 5•104 melanoma cells/well were loaded 
onto the endothelial cells in serum-free medium and left for different time intervals. Non-
attached cells were washed and remaining cells were fixed using ethanol/acetic acid 
(95/5) at -20ºC for 5 min. Melanoma cells adhered to endothelial cells were photographed 
and counted using the Image-Pro Plus software. 
3.3 Measurement of adhesion forces between melanoma and 
endothelial cells using atomic force microscopy (AFM) 
Instrumentation: Experiments were performed with an Asylum MFP-3D type 
atomic force microscope (Asylum Research), having an Axiovert 200 microscope as a 
support, and the MFP-3D Xop driver program, written in Igor Pro software (v. 6.22A, 
Wavemetrics). Silicon nitride tipless cantilevers were used (MikroMasch). Their spring 
constant was defined by thermal calibration method (Hutter, Bechhoefer 1993), giving an 
average of 30 pN/nm. Cantilevers were functionalized with a multilayer build-up, covered 
with biotinylated-BSA, streptavidin and with biotinylated Concanavalin-A (Vegh et al. 
2012, Zhang, Wojcikiewicz & Moy 2006). 
Experimental setup: 10
3
 OG-labeled A2058 cells were placed into a 10 cm
2
 
culture dish containing an approximately 2 cm
2
 area of confluent D3 culture in the middle 
of the dish. Force measurements (see below) were performed in Leibovitz L-15 medium 
(Sigma). After 25 min, the medium was replaced with fresh Leibovitz L-15 medium or 
one containing 10 µM Y27632 (T=0). Force measurements were continued for 90 min 
from this time point. 
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Force measurements: Immediately after addition of melanoma cells into the 
endothelial cell-containing culture dish, before their attachment to the endothelium or the 
surface of the dish, a single melanoma cell was brought into contact with the very end of 
the cantilever in order to achieve the attachment between them. The position of the 
melanoma cell on the cantilever was monitored continuously during the experiment, and 
no considerable change occurred. The melanoma cell-containing cantilever was brought 
in contact with the endothelial monolayer with a frequency of 0.033 Hz. The travel speed 
of the “cell probe” was set to 2 µm/s both for lowering (trace) and for pulling back 
(retrace). The total loading force applied was 2 nN. The intercellular adhesion forces were 
determined from the retrace curves by calculating the relative level difference between 
the maximal downward deflection of the cantilever and its alignment after total unbinding 
(Figure 3). As described previously (Vegh et al. 2012), the total adhesion force consists of 
elementary forces, which present as stair-like jumps on the retraction (retrace) phase of 
the force curve (Figure 3, inset).  
 
Figure 3: Measurement of adhesion forces using atomic force microscopy. Force curve (force vs. 
measurement time) of melanoma-endothelial interaction. Trace is plotted with grey and retrace is 
shown in black. The insert shows stair-like ruptures representing the elementary forces of the total 
adhesion force (top). Schematic representation of the position of the endothelium, the melanoma cell-
containing cantilever and the direction of the movement of the cantilever (arrow) (bottom). 
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A homemade MatLab (MathWorks) routine was developed to extract total 
adhesion force values, and statistics to quantify the number and average size of stair-like 
jumps. Individual jumps on retract curves were identified as the level difference between 
two adjacent points passing a threshold. Two fold of the standard deviation taken from the 
last 50 points of each curve was given as threshold. Ten forces were recorded for each 
load (respectively dwell time) starting from low up to high values successively, followed 
by reverse direction recording from high to low values. Finally, the averages and standard 
deviations of corresponding values were calculated, and presented. Using this technique 
we eliminated the possible tip-induced alterations of applying unidirectional variation of 
load and dwell time.  
3.4 Immunofluorescence and phalloidin staining of the actin-
cytoskeleton 
RBECs (P0 or P1) were cultured until confluence on collagen/fibronectin-coated 
glass coverslips. Melanoma cells (A2058 or B16/F10) were fluorescently labeled using 
CellTracker™ Blue CMAC (Invitrogen) or OG and plated onto the endothelial 
monolayer. After 5 h cells were washed and fixed with ethanol/acetic acid. After blocking 
with 3% BSA (Sigma) for 30 min, coverslips were incubated with primary antibodies 
against occludin, claudin-5 or ZO-1 (Zymed) or cleaved caspase-3 (Cell Signaling). The 
staining was visualized using Cy3- or Cy5-conjugated secondary antibodies. In apoptosis 
studies number of cleaved caspase-3 positive endothelial cells was compared to the total 
EC number. Three-dimensional optical sectioning was performed using an Olympus 
Fluoview FV1000 confocal laser-scanning microscope with spectral detectors. Using the 
Olympus Fluoview software (version 1.7.2.2), OG and Cy3 images were pseudocolored 
green and red, respectively. 
Melanoma cells cultured alone on glass coverslips were fixed with 4% 
formaldehyde and permeabilized using acetone at -20°C for 10 min. After blocking cells 
were stained with Alexa488-phalloidin (LifeTechnologies). Mounting was performed in 
anti-fading embedding medium (Biomeda) and the distribution of the signal was studied 
using a Nikon Eclipse TE2000U photomicroscope with epifluorescent capabilities 
connected to a digital camera (Spot RT KE). 
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3.5 Measurement of transendothelial electrical resistance 
(TEER) 
RBECs were grown on collagen/fibronectin-coated semipermeable filters (0.4 μm 
pore size, 1.12 cm
2
, Costar Corning Transwell Clear). After reaching confluency, the 
endothelial monolayer was supplied with 550 nM hydrocortisone, 250 μM CPT-cAMP 
(Sigma) and 17.5 μM RO-201724 (Roche) and placed into the wells of the CellZscope® 
instrument (nanoAnalytics) containing astrocyte conditioned medium. After TEER had 
reached plateau, 10
5
 melanoma cells were plated into the apical chamber and TEER was 
followed for 24 h. 
3.6 Transmigration experimental setup 
For transmigration experiments, primary RBECs were gently trypsinized and 
passed onto fibronectin/collagen-coated filter inserts (8 μm pore size, 1.13 cm2, 
Millipore) which were placed in 12-well plates.  
 
Figure 4: Use of the in vitro model for brain metastasis investigations. Fluorescently labeled cancer 
cells were plated on confluent endothelial cultures (A). At the end of the co-culture (B) cells from the 
upper compartment were removed (C). Fluorescence microscopy images of the A2058 melanoma cells 
at the end of co-culture (D) and after wiping off the cells from the apical side of the filter 
(transmigrated cells, E). 
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After reaching confluency, endothelial cells were supplemented with 550 nM 
hydrocortisone, 250 μM CPT-cAMP (Sigma) and 17.5 μM RO-201724 (Roche) from the 
apical side and astrocyte conditioned medium from the basolateral side for 24 h in order 
to tighten the junctions. 10
5
 OG-labeled melanoma cells were plated into the upper 
compartment onto the endothelial monolayer in serum-free medium. The lower 
compartment was loaded with serum-free medium containing 100 μg/ml type I collagen. 
Pefabloc
®
 (200 μM) or Y27632 (10 μM) was added to both the apical and basolateral side. 
Cells were left for 5 h, followed by fixation with ethanol/acetic acid. Cells from the upper 
compartment were removed with a cotton swab and melanoma cells migrated through the 
endothelial monolayer and through the pores of the filter were counted (Figure 4). 
3.7 Western-blot analysis 
Melanoma cells were plated onto confluent brain endothelial cells (RBEC or D3) 
in serum-free medium and left for 24 h. Cells were washed with PBS and scraped into 
ice-cold lysis buffer (20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 1% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate, 1 mM sodium vanadate, 10 mM NaF, 1 
mM EDTA, 1 mM Pefabloc
®
) and incubated on ice for 30 min. Lysates were clarified by 
centrifugation at 10,000•g for 10 min at 4°C. Proteins were electrophoresed and blotted 
onto PVDF (Millipore) or nitrocellulose (Whatman) membranes. Blocking the 
nonspecific binding capacity of the membranes was carried out at room temperature for 
30 min in TBS-T containing either 5% casein (nonfat milk powder) or 3% BSA in the 
case of claudin-5. Anti-claudin-5 (Zymed) and anti-occludin (Transduction Laboratories) 
primary antibodies were used. After washing the membranes in TBS-T, blots were 
incubated with the secondary antibodies (Pierce) diluted in TBS-T. The immunoreaction 
was visualized using the Immobilon Western Chemiluminescent HRP Substrate 
(Millipore) on X-ray film (Agfa). 
3.8 Zymography 
D3 cells were grown in 12-well plates. 2•105 A2058 melanoma cells were plated 
onto the endothelial monolayer in serum-free medium and left for 5 h. Culture media 
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were collected, clarified by centrifugation at 10,000•g for 10 min on 4°C and prepared in 
mercaptoethanol-free Laemmli buffer. Cells were washed and lysed in ice cold TBS 
containing 1.5% Triton X-114. Samples were centrifuged at 4°C and the supernatants 
were placed to 37°C for 5 min. After centrifugation at room temperature for 2 min the 
upper aqueous phase was thrown away and the membrane fraction was dissolved in 
mercaptoethanol-free Laemmli buffer. Samples were electrophoresed under non-
denaturing conditions in a polyacrylamide gel containing 1.5 mg/ml gelatin. Gels were 
washed two times in 2.5% Triton X-100 and two times in water and incubated for two 
days at 37°C in a buffer containing 50 mM Tris pH=7.4, 5 mM CaCl2, 1 mM ZnSO4, 1 
mM MgCl2 and 0.2 M NaCl or 50 mM Tris pH=7.4, 0.2 M NaCl and 5 mM EDTA. Gels 
were stained with Coomassie BBR-250 for 20 min and destained using 10% methanol and 
10% acetic acid until the gelatinolytic bands became visible. 
3.9 Silencing by RNA interference 
Stealth
TM
 siRNA duplex oligoribonucleotides were designed using Life 
Technologies BLOCK-iT
TM
 RNAi designer and were purchased from Life Technologies. 
The sequences used are summarized in Table 1. A2058 cells were plated at 50% 
confluency. Transfection of oligonucleotides was performed in OptiMEM medium (Life 
Technologies) containing 20 nM RNA and DharmaFECT4 transfection reagent (Thermo 
Scientific) following the manufacturer's instructions when ROCK I-II were silenced. 
Specific knock-down of seprase was performed in OptiMEM medium containing 10 nM 
RNA and Lipofectamine
TM
 RNAiMAX reagent (Invitrogen) following the manufacturer's 
instructions. After 8 h the medium was changed to regular culture medium. In order to 
increase the efficiency, a second transfection was performed the following day. Cells 
were used 24 h after the second transfection. At the same time transfection efficiency was 
analyzed by real-time PCR. 
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Name   Sequence (5' -3') 
ROCK I sense UAGAGUGUCGAAGAUGCCAUGUUAA 
antisense UUAACAUGGCAUCUUCGACACUCUA 
ROCK II sense CCGUUGCCAUAUUAAGUGUCAUAAA 
antisense UUUAUGACACUUAAUAUGGCAACGG 
Seprase sense AAGAAGUGUGUUACUUGCCAUCUAA 
antisense UUAGAUGGCAAGUAACACACUUCUU 
Control sense GACGUAGAGAGAGUUCCGACAUACA 
antisense UGUAUGUCGGAACUCUCUCUACGUC 
Table 1: Stealth siRNA sequences used for silencing of ROCK-I, -II and seprase. 
3.10 Evaluation of brain metastasis formation in vivo 
7-10 week old C57BL/6 male mice were anaesthetized with Avertin (Fluka) 
administered intraperitoneally (30 mg/100 g body weight in a volume of 0.35 ml). 10
6
 
B16/F10 melanoma cells were injected in 200 μl Ringer-HEPES solution into the right 
common carotid artery using a syringe with a 30-gauge needle. Following inoculation of 
tumor cells 500 µg/kg Y27632 was administered intravenously to some animals. After 10 
days animals were sacrificed (terminal anaesthesia with Avertin), transcardially perfused 
with phosphate buffered saline (PBS, 10 mM, pH = 7.4), followed by 3.5% 
paraformaldehyde (Sigma) in PBS. Brains were removed and placed into the same 
fixative overnight at 4°C. After postfixation brains were cryoprotected in 30% sucrose (in 
10 mM PBS) for at least 2 days at 4°C. 50 µm cryosections were prepared and melanotic 
lesions were counted. Only parenchymal metastases (at a distance of at least 500 µm from 
the meninges and ventricles) were considered. All mice were housed and treated in 
accordance with widely accepted standards and the protocols were approved by the 
institutional care and the regional committee for animal research. 
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4 Results 
4.1 Interaction of melanoma cells with the in vitro BBB model: 
adhesion and transmigration 
In the process of brain metastasis formation, the ability of tumor cells to adhere to 
cerebral endothelial cells has a critical role. To assess metastatic melanoma cells’ 
adhesion ability we employed an in vitro model of the blood-brain barrier. Melanoma 
cells were seeded onto confluent cerebral endothelial cells (D3 or RBEC). We observed 
that both A2058 and B16/F10 melanoma cells were able to adhere to endothelial cells. In 
our experimental setup, we observed that melanoma cells started to attach to endothelial 
monolayers early, approximately 15 min after seeding. The number of adherent 
melanoma cells increased in time (Figure 5). 
 
 
Figure 5: Adhesion of melanoma cells to brain endothelial cells. Fluorescently labeled melanoma cells 
(A2058 or B16/F10) (2.5•104/cm2) were plated onto confluent CECs (RBEC or D3) and left for 
different time intervals. After washing of non-adherent cells, attached melanoma cells were counted. 
When parallely the same numbers of A2058 or B16/F10 cells were plated onto 
confluent brain endothelial monolayers, B16/F10 cells attached in a higher number to the 
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endothelium than A2058 cells. Comparing the two endothelial monolayers, both 
melanoma cell types adhered much easier to the human cell line than to primary rat cells. 
Attachment of melanoma cells to endothelial cells precedes their penetration 
beneath the endothelial monolayer. Indeed, in our transmigration experiments melanoma 
cells were able to migrate through CECs. The transendothelial migration of melanoma 
cells could be visualized by z-stack laser confocal microscopy images. Endothelial cells 
were grown on coverslips and melanoma cells were plated onto the apical (luminal) side 
of the monolayer (“above” endothelial cells). The cellular processes extended by 
melanoma cells reaching the basolateral side of endothelial cells could be observed closer 
to the coverslip than the tight junctions of endothelial cells (“beneath” endothelial cells) 
(Figure 6).  
 
Figure 6: Migration of melanoma cells from the apical to the basolateral side of CECs. RBECs were 
grown on glass coverslips. A2058 melanoma cells labeled with OG (green cell) were plated onto 
confluent endothelial monolayers. After 5 h cells were washed, fixed and tight junctions were stained 
with anti-ZO-1 antibody (red). Samples were analysed by confocal laser scanning microscopy. A: xy-
stack at the level of the green lines on B and C. B, C: z-stacks along the vertical and horizontal line, 
respectively on A. 
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4.2 Effects of melanoma transmigration on BBB integrity 
4.2.1 Melanoma cells impair the integrity of endothelial barrier 
The appearance of melanoma protrusions beneath the endothelial monolayer led 
us to investigate how the presence of melanoma cells affects the integrity of the 
endothelial barrier. The barrier properties of endothelial monolayers can be determined by 
the measurement of transendothelial electrical resistance (TEER). 5 h after seeding of 
melanoma cells, the more invasive B16/F10 already reduced the TEER values of CECs. 
In the case of A2058 we observed a time dependent fall in the endothelial resistance, to a 
decrease reaching 30% at 24 h (Figure 7).  
 
Figure 7: Changes in the transendothelial electrical resistance in the presence of melanoma cells. 
RBECs were grown on semipermeable filters with 0.4 μm pore size. TEER was followed using the 
CellZscope system. N = 2, * = P<0.05 as assessed by ANOVA and Bonferroni’s post hoc test. 
4.2.2 Paracellular transmigration of melanoma cells induces disassembly 
of endothelial tight junctions 
Regarding the path of transmigration much of our knowledge comes from 
experiments with leukocytes, which are able to transmigrate both between (paracellularly) 
and through (transcellularly) endothelial cells. The paracellular space between adjacent 
ECs is sealed by tight junctions. The drop in the transendothelial electrical resistance of 
the cells indicated a possible damage of the junctional complex. Therefore, in our 
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experiments we have focused on the investigation of the paracellular migration of 
melanoma cells. 
Hence, we have examined changes in the localization and expression of the main 
tight junction proteins. Figure 8 shows that melanoma cells tended to adhere to brain 
endothelial cells in small clusters and were able to disrupt the continuous membrane 
staining of transmembrane TJ proteins (occludin and claudin-5), and the cytoplasmic 
plaque protein ZO-1. As shown in Figure 8, panel A, the first affected TJ proteins were 
transmembrane proteins, since claudin-5 disappeared totally at 2 h co-culture from the 
same place where ZO-1 staining was only partly disrupted. At 5 h after plating of 
melanoma cells onto CECs, no difference was observed between the localization changes 
of the different junctional proteins. Small clusters of A2058 cells adhered to CECs 
induced the disappearance of claudin-5, ZO-1 (Figure 8, panel B) and occludin (Figure 8, 
panel C) from the intercellular contacts. We could observe the same phenomenon in case 
of B16/F10 cells (Figure 8, panel D). 
These results suggest that melanoma cells are able to take the paracellular pathway 
of transmigration. This was also supported by our Western-blot experiments (Figure 9). 
As expected, neither A2058 nor B16/F10 cells expressed claudin-5 or occludin, which 
were present in both RBEC and D3 brain endothelial cells. The claudin-5 signal was 
strongly decreased by both melanoma cell lines in RBECs (Figure 9, panel A) and 
disappeared completely from D3 cells (Figure 9, panel B), while melanoma conditioned 
media induced a less pronounced effect. Similar tendencies could be observed in case of 
occludin (Figure 9, panel C and D), where the degradation products could also be 
visualized in D3 cells in the presence of B16/F10 cells or conditioned medium (Figure 9, 
panel D).  
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Figure 8: Disruption of interendothelial tight junctions induced by melanoma cells. Fluorescently 
labeled (A, B: CellTracker™ Blue, C, D: OG) melanoma cells (A, B, C: A2058 or D: B16/F10) were 
plated onto confluent brain endothelial cells (RBECs) and left for 2 (A) or 5 h (B-D). After washing of 
non-attached melanoma cells samples were fixed and stained for claudin-5, ZO-1 or occludin. Arrows 
indicate sites of disrupted junctions. Scale bar = 50 µm. 
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Figure 9: Changes in the total amount of endothelial junctional proteins in the presence of melanoma 
cells or melanoma-released factors. Melanoma cells or melanoma conditioned media were placed onto 
confluent brain endothelial cells (A, C: RBEC; B, D: D3) and the amount of claudin-5 (A, B) or 
occludin (C, D) was assessed by Western-blot analysis. 
Our data underscore that melanoma cells are able to disrupt the junctions of CECs 
and transmigrate through the paracellular pathway.  
4.2.3 Interaction between melanoma and cerebral endothelial cells induces 
EC apoptosis 
Metastatic tumor cells may facilitate their extravasation not just by disrupting the 
cell-cell junctions but also by inducing endothelial apoptosis. Melanoma cells induced a 
4.7 fold increase in the number of apoptotic brain endothelial cells (from 1.7% in the 
absence of A2058 cells to 7.54%) as visualized by anti-cleaved caspase-3 staining (Figure 
10). No difference in the number of apoptotic melanoma cells was observed in the 
presence or absence of CECs (not shown). 
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Figure 10: Induction of endothelial apoptosis by melanoma cells. RBECs were cultured on glass 
coverslips. A2058 melanoma cells labeled with CellTracker™ Blue were plated onto confluent 
endothelial monolayers. After 24 h cells were washed and fixed. Tight junctions were stained with 
anti-ZO-1 antibody (marker of endothelial cells), while apoptotic cells were visualized using anti-
cleaved caspase-3 antibody. Apoptotic endothelial cells were counted. N = 2, * = P<0.05 as assessed by 
Student’s t-test. 
4.3 Role of proteolysis in melanoma transmigration 
Expression and release of proteases during tumor cell migration has a critical role 
in the invasion of the host microenvironment. Endothelial cells encounter migrating 
melanoma cells, which may secrete proteases in order to facilitate their exravasation. 
To address this phenomenon we have investigated the production of proteases by 
A2058 and B16/F10 melanoma cells in the presence and absence of brain endothelial 
cells by gelatin zymography. Proteolytic enzymes both released in the culture medium 
(Figure 11, panel A) and their membrane bound forms (Triton X-114 fraction) (not 
shown) were analyzed. We have observed that both melanoma cell lines expressed several 
gelatinolytic proteases and their amount increased when melanoma cells were plated onto 
brain endothelial cells. Unexpectedly, the gelatinolytic bands did not disappear in the 
presence of the matrix metalloproteinase inhibitor EDTA (Figure 11, panel A). 
Addition of E-64, an irreversible, potent and highly selective cysteine protease 
inhibitor had no effect on the release of gelatinolytic enzymes. However, addition of 
Pefabloc®, an irreversible serine protease inhibitor to the cells, induced the almost 
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complete disappearance of the proteolytic bands from both the supernatant and the cell 
lysate fraction. This indicates that gelatinolytic serine proteases are produced by 
melanoma cells in large amounts especially when coming in contact with endothelial 
cells. 
We have also observed that presence of Pefabloc® significantly reduced the 
transendothelial migration rate of both A2058 (Figure 11, panel B) and B16/F10 
melanoma cells (to 58%±4% in case of A2058 and to 44%±11% in case of B16/F10 (not 
shown)). 
 
Figure 11: Role of gelatinolytic serine proteases produced by melanoma cells. A: Melanoma cells were 
plated onto confluent monolayers of cerebral endothelial cells or into empty culture dishes in serum-
free medium in the presence or absence of E64 or Pefabloc® and left for 5 h. Culture media were 
collected, then samples were electrophoresed in non-denaturing conditions and the gels were 
incubated in EDTA-containing buffer for 2 days. Proteolytic bands of culture media (A) were 
visualized by Coomassie blue staining. B: RBECs were grown until confluency on 8 µm pore size 
filter inserts. Fluorescently labeled A2058 melanoma cells were plated into the upper chamber in the 
presence or absence of Pefabloc® and left for 5 h. Cells from the upper chamber were removed using 
a cotton swab, and melanoma cells migrated through the endothelial cell layer and the pores of the 
filter were counted. N = 3, * = P<0.05 as assessed by Student’s t-test. 
As a next step we wanted to identify which serine proteases were expressed by 
melanoma cells. One of the most well characterized serine protease with gelatinolytic 
activity is seprase. A2058 melanoma cells expressed a 170 kDa gelatinolytic membrane-
bound serine protease (Figure 12, panel A) in their cell membrane. After silencing of the 
seprase gene the 170 kDa gelatinolytic band disappeared from the zymogram (Figure 12, 
panel A). Therefore, we could identify seprase as one of the gelatinolytic serine proteases 
expressed by A2058 cells. Silencing of seprase in A2058 melanoma cells induced a more 
than 20% decrease in the number of cells transmigrated through brain endothelial cells 
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(Figure 12, panel B). These data suggest that seprase plays an important, but not a unique 
role among proteases involved in the transmigration of melanoma cells through the BBB. 
 
Figure 12: Role of seprase in the transmigration of A2058 cells through brain endothelial cells. A: 
Seprase was silenced in A2058 cells (fold change = 0.09 compared to scrambled RNA-transfected 
cells, determined by real-time PCR). Melanoma cells were plated onto confluent monolayers of 
cerebral endothelial cells or into empty culture dishes in serum-free medium and left for 5 h. Cells 
were lysed in Triton X-114 containing buffer. Zymography was performed in the presence of EDTA. 
Arrow indicates seprase. B: Seprase-silenced or scrambled RNA-transfected A2058 cells were plated 
onto confluent RBECs grown on 8 µm pore size filter inserts. Transmigration assay was performed 
and melanoma cells reaching the bottom of the filter inserts were counted. N = 3, * = P<0.05 as 
assessed by Student’s t-test. 
The increased proteolytic activity of melanoma cells in the presence of endothelial 
cells implied that melanoma transmigration requires extracellular proteolysis. The mode 
of migration that involves proteases is Rac-driven, with low Rho-Rho kinase activity, 
known as mesenchymal movement. 
29 
 
 
 
 
4.4 Role of the Rho/ROCK signaling pathway in the 
transmigration of melanoma cells 
4.4.1 Rho/ROCK inhibition fosters the mesenchymal phenotype of 
metastatic melanoma  
To elucidate the role of the mesenchymal phenotype in melanoma adhesion and 
transmigration we investigated the effect of ROCK inhibition on melanoma cell 
morphology. A2058 and B16/F10 were seeded onto collagen-coated coverslips in the 
presence or absence of Y27632. At 90 min after plating untreated cells had a rounded or 
slightly elongated morphology with several membrane blebs. Upon ROCK inhibition 
melanoma cells adopted an elongated, fibroblastoid morphology with actin-rich 
protrusions and several filopodia (Figure 13, panel A). 
 
Figure 13: Effect of Y27632 on the morphology and protease activity of melanoma cells. A: A2058 or 
B16/F10 melanoma cells were seeded onto collagen-coated surfaces in the presence or absence of 
10 µM Y27632. After 90 min cells were fixed and stained with Alexa488-labeled phalloidin. B: A2058 
melanoma cells were pretreated or not for 90 min with Y27632, then plated onto confluent 
monolayers of D3 cerebral endothelial cells in serum-free medium in the presence of Y27632 and left 
for 5 h. Culture media (supernatants) were electrophoresed in non-denaturing conditions and the gels 
were incubated in EDTA-containing buffer for 2 days. Proteolytic bands of culture media were 
visualized by Coomassie blue staining. 
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Moreover, the ROCK inhibitor Y27632 increased the proteolytic activity of 
melanoma cells (Figure 13, panel B). Inhibition of Rac, however, diminished the increase 
of proteolytic activity (not shown). These suggest that inhibition of ROCK induces a shift 
of melanoma cells to the mesenchymal type of morphology. 
4.4.2 Mesenchymal phenotype of melanoma cells enhances their adhesion 
to the cerebral endothelium 
As a next step we investigated the effect of the inhibition of ROCK on the 
attachment of melanoma cells to monolayers of cerebral endothelial cells. A2058 
melanoma cells were seeded onto hCMEC/D3 (D3) endothelial monolayers in the 
presence or absence of 10 µM Y27632 for 90 min. Inhibition of ROCK led to a 
significant increase in the number of melanoma cells attached to the endothelium (Figure 
14, panel A). In control conditions the ratio of elongated vs. rounded melanoma cells 
attached to the endothelium was 1.33, while in the presence of Y27632 a significant shift 
to the elongated morphology was observed (Figure 14, panel A).  
Moreover, silencing of ROCK-I and ROCK-II genes in melanoma cells 
significantly increased their adhesion to the brain endothelium (Figure 14, panel B), 
supporting the role of the Rho/ROCK pathway in melanoma cells in the interaction 
between melanoma cells and brain endothelial cells. Inhibition of both ROCK-I and 
ROCK-II was needed to increase the adhesion of melanoma cells to the brain 
endothelium, since silencing of either ROCK-I or ROCK-II in melanoma cells induced 
only a slight, non-significant increase in the adhesion rate (128.50%±16.26% and 
134.00%±19.80%, respectively, compared to control cells). 
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Figure 14: Effect of ROCK inhibition (Y27632 or ROCK-I and ROCK-II silencing) on the adhesion 
of melanoma cells onto brain endothelial cells. A: Fluorescently labeled A2058 melanoma cells were 
plated onto confluent D3 monolayers and left for 90 min. After washing of non-adherent cells, 
attached melanoma cells were counted. B: ROCK-I and ROCK-II genes were silenced in A2058 
melanoma cells with an efficiency of 49% and 63%, respectively, as assessed by real-time PCR. 
Melanoma cells were fluorescently labeled and plated onto confluent D3 monolayers for 90 min. After 
washing of non-adherent cells, attached melanoma cells were counted. Control = cells transfected 
with a non-targeting RNA duplex. Results are expressed as % control and given as mean ± SD. N = 3, 
*** = P<0.0005, * = P<0.05 as assessed by Student’s t-test. 
4.4.3 Rho-kinase inhibition increases the adhesion forces between 
melanoma cells and endothelial cells 
We were interested whether there is a correlation between increased number of 
attached melanoma cells to endothelium and the adhesion forces between individual 
melanoma cells and endothelial cells. Therefore, we performed single-cell force 
spectroscopy measurements.  
Melanoma cells were immobilized to the very edge of functionalized tipless 
atomic force microscope (AFM) cantilevers and we quantified the total unbinding force 
(adhesion) between the melanoma cell and the endothelial layer.  
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Figure 15: Measurement of melanoma-endothelial adhesion force using AFM. Fluorescently labeled 
A2058 melanoma cells were attached to functionalized tipless AFM cantilevers and pressed against a 
D3 endothelial layer. The adhesion force was quantified as described in the Material and methods. At 
T=0 fresh medium was added containing or not 10 µM Y27632. A: total adhesion force, B: number of 
ruptures, C: size of ruptures. Results are expressed as % control and given as mean ± SD, N = 5. 
When a loading force of 2 nN was applied the total adhesion force was of 200 pN 
in control conditions. We found that inhibition of ROCK led to an increase in the total 
unbinding force between melanoma and endothelial cells, reaching an approximately 2.5-
fold value after 45 min (Figure 15, panel A). Initially the size and later the number of 
individual unbinding events seemed to increase (Figure 15, panel B and C). 
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4.4.4 ROCK inhibition raises the transmigration rate of melanoma cells 
through CECs 
The above presented experiments clearly showed that ROCK inhibition of 
melanoma cells was associated with an increase in the adhesion force and in the number 
of adherent cells. We wondered whether this was accompanied by an increase in the 
number of transmigrating melanoma cells.  
 
Figure 16: Role of ROCK inhibition in the transendothelial migration of melanoma cells. RBECs 
were grown until confluency on 8 µm pore size filter inserts. Fluorescently labeled melanoma cells 
(A2058, B16/F10) were plated into the upper chamber in the presence or absence of 10 µM Y27632 or 
10 µM fasudil and left for 5 h. Cells from the upper chamber were removed using a cotton swab, and 
melanoma cells migrated through the endothelial cell layer and through the pores of the filter were 
counted. Results are expressed as % control and given as mean ± SD, ** = P<0.005; * = P<0.01 as 
assessed by Student’s t-test, N=2-5. 
To address this question melanoma cells were seeded onto endothelial cells 
cultured on filter inserts. In response to ROCK inhibition the number of melanoma cells 
performing transendothelial migration increased significantly: by 2.75 or 2.11 fold in case 
of A2058 melanoma cells treated with Y27632 or fasudil, respectively and by 5.60 fold in 
case of B16/F10 melanoma cells treated with Y27632 (Figure 16). Migration of 
melanoma cells in the absence of endothelial cells was not affected by Y27632 as 
assessed by the wound assay (not shown). 
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4.4.5  Melanoma RhoA inhibition is responsible for the increased 
transmigration rate 
To further investigate the role of Rho/ROCK signaling in melanoma cells during 
transendothelial migration we pretreated either melanoma or endothelial cells with the 
irreversible Rho inhibitor CT04 and performed transmigration experiments (Figure 17).  
 
Figure 17: Role of melanoma RhoA in the transendothelial migration. RBEC(CT04), A2058(CT04) 
and B16/F10(CT04) represent cells pretreated with 1 µg/ml CT04 for 150 min. Transendothelial 
migration was performed for 5 h. Results are expressed as % control (no CT04 pretreatment) and 
given as mean ± SD. N = 2, * = P<0.05 compared to control, as assessed by ANOVA and Bonferroni’s 
post hoc test. 
Pretreatment of endothelial cells with CT04 had no effect on the number of 
melanoma cells migrated through the endothelial monolayer. Conversely, pretreatment of 
melanoma cells with CT04 induced a significant increase in the number of melanoma 
cells migrating from the apical to the basolateral side of the endothelium. The increase 
was 1.51 fold in case of A2058 cells, and 2.43 fold in case of B16/F10 cells. These results 
support that inhibition of the Rho/ROCK pathway in melanoma, but not in brain 
endothelial cells induces a significant increase in the number of melanoma cells migrating 
through the endothelium. 
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4.4.6 ROCK inhibitor promotes melanoma brain metastasis formation in 
vivo 
Finally, we have studied the role of ROCK inhibition on melanoma brain 
metastasis formation in vivo as well. B16/F10 melanoma cells were injected into the 
carotid artery of C57/BL6 syngeneic mice, some of which were additionally administered 
500 µg/kg Y27632 intravenously.  
 
Figure 18: Effect of ROCK inhibition on parenchymal brain metastasis formation in vivo. B16/F10 
melanoma cells were injected into C57/BL6 mice. Y27632 was administered intravenously in a dose of 
500 µg/kg. After 10 days animals were sacrificed and parenchymal metastases were counted in the 
brains. Graph represents mean ± SEM, N = 6, ** = P<0.005 as assessed by Student’s t-test. 
In control conditions, B16/F10 was able to form mainly non-parenchymal 
(meningeal and ventricular) metastases, only 0.67±0.24 parenchymal metastasis per 
mouse could be observed. However, in mice treated with Y27632 the number of 
parenchymal metastases increased significantly to 3.11±0.37 per mouse (Figure 18). 
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5 Discussion  
One of the rate limiting steps of melanoma brain metastasis formation is the 
extravasation through the blood-brain barrier, which requires adhesion of tumor cells to 
cerebral endothelial cells and subsequently their transmigration through the capillary wall. 
In order to understand the mechanisms of melanoma brain metastasis formation we 
applied an in vitro BBB model to study the interaction between melanoma and brain 
endothelial cells. 
5.1 In vitro BBB model for the study of melanoma-endothelial 
interaction 
The in vitro BBB model used in our experiments is based on the culture of 
primary rat brain endothelial cells (RBECs) or the human cerebral endothelial cell line 
hCMEC/D3 (D3). RBECs in our culture system maintain the main in vivo characteristics 
of the brain endothelium, such as expression of von Willebrand factor, presence of a 
continuous line of tight junctions, high transendothelial electrical resistance (TEER) and 
low permeability values and high activity of P-glycoprotein. However, the fact that 
rodents develop in very rare instances spontaneous melanoma brain metastases (Cranmer 
et al. 2005) points towards significant differences between the human and animal disease. 
This makes necessary the use of human endothelial cells despite their inferior 
permeability characteristics. Moreover, it has been shown that human melanoma cells 
injected into mice give spontaneous CNS metastasis (Kienast et al. 2010), therefore a 
xenogeneic model can also be accepted. The hCMEC/D3 cell line (Weksler et al. 2005) is 
the most well characterized human brain endothelial cell line, which has been widely used 
as a human BBB model (Carl et al. 2010, Forster et al. 2008). 
We have used the A2058 cell line, which has been shown to produce brain 
metastasis when injected into immunodeficient mice (Kienast et al. 2010). Additionally 
we have used murine B16/F10 cells, which initially were adapted to form lung metastasis; 
however, they are able to form brain metastases as well (Raz, Hart 1980, Bridle et al. 
2010). 
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Our adhesion experiments revealed that both melanoma cells attached in a higher 
number to D3 cells than to RBECs. This might be due to the difference in the human and 
rat adhesion molecules, but also to the lower tightness of the barrier formed by the human 
cell line.  
We have performed time-lapse video experiments, which demonstrated that 
transmigrated melanoma cells tended to attract other melanoma cells to migrate through 
the endothelial cell layer at the same site. We could also visualize that transmigrated 
melanoma cells moved along the basolateral side of the endothelial monolayer. This is in 
accordance with the observations of Lu et al. (Lu, Bucana & Schroit 2007) who described 
that breast cancer cells injected intracardially into mice extravasated into the brain and 
aligned themselves along the blood vessels, on the basolateral side of endothelial cells, 
suggesting that the tumor cells migrated along the vasculature. This “pericyte-like” 
position of transmigrated tumor cells was also observed by Kienast et al. (Kienast et al. 
2010) using in vivo multiphoton laser scanning microscopy. They have described that 
melanoma and lung cancer cells could only proliferate in the brain if they maintained a 
direct contact to the abluminal side of endothelial cells of cerebral capillaries. These 
results might raise the possibility of a hiding mechanism of tumor cells behind the 
defense lines (especially the MDR-MRP systems) of the BBB. 
5.2 Melanoma cells impair the integrity of the BBB and use the 
paracellular pathway of transmigration 
During transmigration, melanoma cells damaged the integrity of the endothelial 
monolayer, which was supported by the decrease of TEER and the presence of apoptotic 
endothelial cells. These observations are in accordance with previous results showing that 
– in contrast to leukocytes – tumor cells do not leave the endothelium intact after 
diapedesis (Strell, Entschladen 2008). 
Regarding the routes of transmigration, there are two theoretical possibilities, 
which have been intensively studied in the case of leukocytes: the paracellular (through 
the interendothelial junctions) and the transcellular pathway (through single endothelial 
cells). A large number of in vitro and in vivo studies have demonstrated that leukocyte 
diapedesis can occur either by forming a paracellular gap or via the formation of a 
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transcellular pore (Carman 2009, Dejana 2006). The phases and molecular mechanisms 
involved in the extravasation of leukocytes have also been largely characterized. Since the 
CNS is an immunologically privileged site, transendothelial migration of leukocytes 
through the BBB is practically limited to neuroinflammation. Mononuclear cells can 
traverse the inflamed BBB both through the tight junctions (paracellular pathway) 
(Reijerkerk et al. 2006) and transcellularly (Wolburg, Wolburg-Buchholz & Engelhardt 
2005). 
We have shown that melanoma cells are able to disrupt interendothelial junctions 
and to migrate using the paracellular route. However, these results do not exclude the 
possibility that melanoma cells might take the transcellular pathway as well. The 
maintenance of low paracellular permeability of the BBB depends on claudin-5 and 
occludin transmembrane proteins. Interaction between melanoma and endothelial cells 
resulted in disappearance of claudin-5 and occludin from cell junctions and subsequently 
in degradation of these junctional proteins in ECs.  
5.3 Role of proteases in the extravasation of melanoma cells 
The breakdown of the endothelial barrier draw our attention to the possible 
involvement of melanoma-secreted proteases in this process. Tumor cells produce 
proteases, which are required for the intravasation, extravasation and invasion of the 
surrounding tissue. Moreover, tight junction proteins might be targets of proteolytic 
degradation (Reijerkerk et al. 2006) too. 
The plasminogen/plasmin system has been shown to facilitate the transmigration 
of melanoma cells through brain endothelial cells both in vivo and in vitro (Perides et al. 
2006). Melanoma cells are able to express several types of proteases including u-PA 
(Artym et al. 2002), seprase (Monsky et al. 1994, Pineiro-Sanchez et al. 1997) and matrix 
metalloproteinases (Sounni et al. 2002) which have been shown to promote their invasive 
potential. 
Our results demonstrate that during the transendothelial migration process 
melanoma cells express large amounts of both secreted and membrane-bound proteases 
with gelatinolytic activity. Much to our surprise the majority of these enzymes proved to 
be not matrix metalloproteinases, since addition of EDTA to the incubation buffer did not 
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decrease the number and intensity of the proteolytic bands. In contrast, after addition of 
the irreversible serine protease inhibitor Pefabloc
®
 to the culture medium the gelatinolytic 
bands almost completely disappeared and the number of melanoma cells migrated 
through the brain endothelial monolayer decreased significantly. 
We have examined whether among these gelatinolytic serine proteases seprase 
and/or its degradation products were present. Seprase (surface expressed protease) or 
FAPα (fibroblast activation protein α) is a type II transmembrane glycoprotein, originally 
identified in LOX melanoma cells (Pineiro-Sanchez et al. 1997), contributing to the 
invasiveness of melanoma and carcinoma cells (O'Brien, O'Connor 2008). It has two 
types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170 kDa gelatinase 
activity. Dimerization and glycosylation of seprase are necessary for its proteolytic 
activity. Seprase has been identified as a potential marker protease of invasiveness, 
localized on invadopodia of malignant melanoma cells (Monsky et al. 1994). Seprase 
shares homology with dipeptidyl peptidase IV (DPPIV). The latter is expressed by normal 
melanocytes, epithelial and other cells, while seprase is characteristic for tumor and 
proliferating mesenchymal cells (Gilmore et al. 2006, Wesley et al. 1999). Using PCR we 
have found that human brain endothelial D3 cells express DPPIV, but do not express 
seprase, while A2058 human melanoma cells express seprase, but not DPPIV (not 
shown). By gelatin zymography coupled with gene silencing we have shown that A2058, 
but not B16/F10 cells express seprase in the Triton X-114-extractable membrane fraction. 
However, several other gelatinolytic serine proteases were expressed by both melanoma 
cell lines, which did not disappear after seprase-silencing. The identity of these enzymes 
still needs to be elucidated. Accordingly, silencing of seprase reduced to a lesser extent 
the number of transendothelially migrated melanoma cells compared to Pefabloc
®
. A 
recent study has also demonstrated that serine protease inhibition reduced melanoma 
transendothelial migration through non-cerebral human microvascular endothelial cells 
(Voura et al. 2013).  
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5.4 Role of the ROCK inhibition-induced mesenchymal 
phenotype in the interaction of melanoma cells with the 
brain endothelium 
In tumor cell migration the elevated proteolytic activity is associated with the 
mesenchymal phenotype. Migration in mesenchymal mode means that tumor cells acquire 
an elongated morphology, involves firm adhesion and are independent of Rho/ROCK 
regulation (Sahai, Marshall 2003). Owing to the fact that melanoma proteolytic activity 
yielded a higher rate of transmigration through the endothelium, we investigated the 
contribution of Rho/ROCK inhibition in the process.  
We observed that upon Rho/ROCK inhibition melanoma cells acquired an 
elongated shape, with large cellular protrusions. As expected, melanoma cells coming in 
contact with brain endothelial cells produced gelatinolytic proteases, the amount of which 
increased in the presence of the ROCK inhibitor Y27632. Previously, an elevated seprase 
(FAP) expression was observed in the case of invasive glioblastoma cells accompanied by 
a mesenchymal phenotype (Mikheeva et al. 2010). Based on our experiments, ROCK 
inhibition raised significantly the number of adherent melanoma cells to endothelium. 
The Rac1 Rho GTPase is responsible for mesenchymal phenotype (Sanz-Moreno et al. 
2008). Indeed when Rac1 was hindered, melanoma cells adhered in a lower number to 
endothelial cells (data not shown). The involvement of Rac1 signaling and proteolytic 
activity in melanoma metastasis formation has recently been underlined (Shaverdashvili 
et al. 2013).  
Therefore, it is conceivable that the mesenchymal type of cell movement might be 
superior to the amoeboid type during migration of melanoma cells through the brain 
endothelium. 
Using single-cell force spectroscopy, we have measured the melanoma-endothelial 
adhesion force in the absence and presence of Y27632. This method monitors initial steps 
of cell-cell interaction, before firm adhesion is established. As described previously 
(Vegh et al. 2012), the total adhesion force is composed of elementary forces of roughly 
20 pN size. Present as stair-like jumps on the retraction (retrace) phase of the force curve, 
they correspond to individual rupture events between the two cells. The total adhesion 
force can be characterized with the size and the number of elementary jumps. It seems 
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that mainly the elevation of the number of the ruptures is responsible for the ROCK 
inhibitor-induced increase in the total adhesion force; the average size of the ruptures has 
grown only transiently. Accordingly, the adhesion force can also be calculated as the 
number of ruptures (Reeves et al. 2013). 
Theoretically the increased adhesiveness can be due to the increased expression of 
adhesion molecules in endothelial and/or melanoma cells, to the increased affinity and/or 
velocity of the adhesion molecule(s), or to the increase in the number of adhesion 
molecules coming in contact with their target (i.e. increase in the contact surface between 
the two cell types). Cell flattening might result in an increase in the intercellular contact 
area, making more surface molecules accessible. Therefore, the ROCK inhibitor-induced 
morphological changes themselves might be partly responsible for the increase in the 
adhesion force between melanoma and endothelial cells. 
Our data revealed that increased adhesion of melanoma cells was accompanied by 
an elevated rate of transmigration and a significant increase in the number of brain 
metastases in vivo. Using B16/F10 murine melanoma cells we could observe a relatively 
low number of parenchymal brain metastases, which is consistent with literature data 
(Zhang et al. 2009). Leptomeningeal and ventricular metastases were more frequent. 
However – since we wanted to evaluate metastatic cells migrated through the BBB – 
these were not counted; only metastases of at least 500 µm distances from the meninges 
and ventricles were considered. In mice treated with Y27632, the number of parenchymal 
metastases was still low, but significantly higher than in control conditions, which 
confirms our in vitro results. 
According to our results, migration of melanoma cells through the BBB seems to 
depend on tumor but not on endothelial Rho/ROCK signaling and ROCK-I and ROCK-II 
have redundant functions. Brain endothelial tight junction proteins, which were shown to 
be involved in the transmigration of melanoma cells, are linked to the actin cytoskeleton 
and are influenced by ROCKs. Inhibition of Rho/ROCK signaling has been shown to 
prevent Ca
2+
-induced junctional disassembly in both epithelial and brain endothelial cells 
(Samarin et al. 2007, Wilhelm et al. 2007). ROCK enhances BBB permeability via 
disruption of tight junction proteins in subarachnoid hemorrhage (Fujii et al. 2012), while 
inhibition of ROCK was found to attenuate the HIV-1 Tat protein-induced decrease in 
occludin levels in brain endothelial cells (Xu et al. 2012).  
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These data indicate that inhibition of the Rho/ROCK pathway prevents the 
disruption of the tight junctions in different pathological conditions. Moreover, the ROCK 
inhibitor Y27632 increased the transendothelial electrical resistance of cerebral 
endothelial cells (unpublished results). Therefore, it is not surprising that the increase in 
transendothelial migration rate of melanoma cells was not due to the inhibition of 
endothelial Rho/ROCK pathway. However, Li et al. (Li et al. 2006) have observed that 
inhibition of endothelial ROCK with Y27632 or overexpression of a ROCK dominant-
negative mutant in endothelial cells prevented NCI-H209 small cell lung cancer cells to 
migrate through a brain endothelial monolayer. These data suggest that different tumor 
cell types may activate different mechanisms during transendothelial migration. 
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In conclusion, our in vitro results suggest that during brain metastasis formation 
melanoma cells damage the integrity of the BBB by inducing apoptosis of endothelial 
cells and by disrupting the continuity of the tight junctions. Transmigrating melanoma 
cells are able to use the paracellular pathway to overcome the cerebral endothelial 
monolayer and seem to be able to hide behind the defense lines of the BBB.  
During their transendothelial migration, melanoma cells produce serine proteases 
capable of degrading the components of the basement membrane of capillaries. Inhibition 
of these proteases can significantly reduce the number of extravasating melanoma cells.  
Our data demonstrate that inhibition of the Rho/ROCK pathway in melanoma 
cells enhances transmigration of melanoma cells through the BBB. We have identified the 
increased attachment of melanoma cells to the brain endothelium as an underlying 
mechanism. It may be hypothesized that this might depend on the flattening of melanoma 
cells.  
Our data suggest that the mesenchymal type of cell movement (characterized by: 
low ROCK activity, increased proteolysis and elongated morphology) is more important 
than the amoeboid type during migration of melanoma cells through the brain 
endothelium. 
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6 Summary 
Brain metastases represent the majority of intracranial tumors and are associated 
with high morbidity. Because CNS lacks lymphatic circulation, during brain metastasis 
formation tumor cells have to migrate through cerebral endothelial cells, which form the 
morphological basis of the blood-brain barrier (BBB). Melanoma has the highest 
propensity to metastasize to the brain; however, the mechanisms of interaction of 
melanoma cells with endothelial cells of the blood-brain barrier are incompletely 
understood. 
In order to gain insights into plausible mechanisms involved in this process we 
have used an in vitro experimental setup based on the culture of cerebral endothelial cells 
and melanoma cell lines, respectively. 
We have demonstrated that during brain metastasis formation, melanoma cells 
impair the integrity of the BBB by inducing apoptosis of endothelial cells and by 
generating discontinuity of the tight junctions. Melanoma cells migrate paracellularly to 
penetrate beneath the endothelial monolayer. 
We have shown that transendothelial migration of melanoma cells is enhanced by 
expressed and secreted serine proteases, including seprase. Inhibition of these proteases 
decreases the rate of transendothelial migration.  
In addition, we have investigated the possible involvement of the Rho/ROCK 
signaling pathway in melanoma BBB crossing.  
Our experiments revealed that inhibition of the Rho/ROCK pathway in melanoma 
cells enhances transmigration through the BBB. We have identified the increased 
attachment of melanoma cells to the brain endothelium as an underlying mechanism.  
Our data indicate that the mesenchymal type of cell movement (characterized by: 
low ROCK activity, increased proteolysis and elongated morphology) is more important 
than the amoeboid type during migration of melanoma cells through the brain 
endothelium. 
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